Journal of Neonatal Surgery
ISSN(Online): 2226-0439
Vol. 14, Issue 14s (2025)
https://www.jneonatalsurg.com

OPEN ACCESS

Ashwagandha as an Adaptogen: Evidence-Based Role in Alleviating Stress and Anxiety

Dr.K. Chitra devi[1], Prof Ankita Bohare[2], Dr. Dhiraj Kumar Yadav[3], Dr. Ruchita Shrivastava[4], Dr.L. Nivetha[*5]

[1]Professor, Department of Microbiology, School of Allied Health Science, Shri Indra Ganesan, Institute of Medical Science, Trichy-12

[2]Dept of Zoology & Biotechnology, Govt Science College, Jabalpur M.P.

[3]Senior Assistant Professor, Department Of Farm Forestry, UTD, SANT GAHIRA GURU, UNIVERSITY SARGUJA, Ambikapur, Chhattisgarh, India

[4]Guest Lecturer, Department of Botany, Govt. Homescience PG Lead College, Narmadapuram, Madhya Pradesh

5*Dr.L.Nivetha,, Assistant professor, Department of Biotechnology, PSGCAS

***Corresponding Author**

Email ID: nivedha.laxman@gmail.com

Cite this paper as: Dr.K. Chitra devi, Prof Ankita Bohare, Dr. Dhiraj Kumar Yadav, Dr. Ruchita Shrivastava, Dr.L. Nivetha, (2025) Ashwagandha as an Adaptogen: Evidence-Based Role in Alleviating Stress and Anxiety. *Journal of Neonatal Surgery*, 14 (14s), 115-118.

ABSTRACT

Withania somnifera, commonly known as Ashwagandha, is an important medicinal plant widely recognized for its adaptogenic and anxiolytic effects. In recent years, growing interest has emerged in its role as a natural remedy for stress and anxiety disorders. This review explores the scientific evidence supporting the use of Ashwagandha in managing psychological stress and anxiety. Various clinical trials and experimental studies suggest that Ashwagandha can effectively reduce cortisol levels, improve mood, and enhance overall stress resilience. The mechanisms behind these effects include modulation of the hypothalamic-pituitary-adrenal (HPA) axis, antioxidant activity, and interaction with neurotransmitters. Given its safety profile and therapeutic potential, Ashwagandha may serve as a valuable complementary treatment in stress and anxiety management.

Keyword: *Ashwagandha, Withania somnifera, stress management, anxiety, adaptogen, cortisol, HPA axis, withanolides*

1. INTRODUCTION

Stress and anxiety have become significant public health concerns in the modern world, affecting both physical and mental well-being. According to the World Health Organization, anxiety disorders are among the most prevalent mental health conditions globally, contributing to disability and reduced quality of life. Chronic stress is closely linked with several health problems, including hypertension, cardiovascular disease, depression, and weakened immune function (WHO, 2021).

Pharmacological treatments such as benzodiazepines, selective serotonin reuptake inhibitors (SSRIs), and serotonin-norepinephrine reuptake inhibitors (SNRIs) are commonly prescribed for stress and anxiety management. While these medications can be effective, they are often associated with adverse effects such as sedation, tolerance, dependence, and withdrawal symptoms (Baldwin et al., 2014). As a result, there is growing interest in complementary and alternative approaches that are safer and more sustainable for long-term use.

One such alternative is Withania somnifera, commonly known as Ashwagandha, an herb extensively used in traditional Ayurvedic medicine. Classified as a Rasayana (rejuvenator), Ashwagandha is believed to promote longevity, increase energy, and improve resistance to stress. Modern pharmacological studies have identified its adaptogenic properties, making it a promising candidate for stress and anxiety reduction (Singh et al., 2011).

The active constituents of Ashwagandha, including withanolides, alkaloids, and sitoindosides, are known to influence the hypothalamic-pituitary-adrenal (HPA) axis, a key system involved in the body's response to stress. By regulating cortisol secretion and enhancing neurotransmitter balance, Ashwagandha helps restore physiological homeostasis under stress conditions (Chandrasekhar et al., 2012).

Given the increasing demand for natural and effective treatments for mental health issues, this review aims to critically evaluate the scientific literature on the use of Ashwagandha in stress and anxiety management. It will explore the

phytochemistry, mechanisms of action, clinical evidence, and safety profile of Ashwagandha, offering insights into its therapeutic potential as a complementary remedy.

As an adaptogen, Ashwagandha helps modulate the body's stress response by influencing neuroendocrine pathways, including the hypothalamic-pituitary-adrenal (HPA) axis (Panossian & Wikman, 2008)."

2. METHODOLOGY:

This review was conducted to evaluate the therapeutic role of Withania somnifera (Ashwagandha) in stress and anxiety management. A systematic search was carried out using databases including PubMed, Scopus, ScienceDirect, and Google Scholar, covering literature from 2000 to 2024. Keywords such as "Ashwagandha," "Withania somnifera," "stress," "anxiety," "adaptogen," and "HPA axis" were used with Boolean operators.

"Withanolides and glycowithanolides are the primary bioactive components responsible for anxiolytic and antidepressant-like activity, likely mediated via GABA-mimetic effects and cortisol reduction (Bhattacharya et al., 2000)."

Additionally, Ashwagandha has been shown to promote neuritic regeneration and synaptic repair, which may explain its neuroprotective and mood-stabilizing properties (Kuboyama et al., 2005).

Studies included were peer-reviewed, in English, and focused on preclinical or clinical evaluation of Ashwagandha for stress or anxiety. Excluded were non-relevant, non-English, or low-quality sources without clear outcomes. Both in vitro, in vivo, and human trials were reviewed.

Data were extracted on study type, dosage, duration, outcomes (e.g., cortisol levels, stress scales), and safety. Findings were categorized into mechanism of action and clinical efficacy.

Ashwagandha's mechanism primarily involves modulation of the hypothalamic-pituitary-adrenal (HPA) axis, reduction of cortisol, and interaction with GABAergic pathways. Its antioxidant and anti-inflammatory properties also contribute to neuroprotection and stress relief.

Clinical trials show promising results. In one randomized controlled trial, Ashwagandha root extract significantly reduced cortisol levels and stress scores compared to placebo (Chandrasekhar et al., 2012). Other studies reported improved sleep, reduced anxiety symptoms, and enhanced well-being without significant adverse effects.

The reviewed evidence supports the adaptogenic, anxiolytic, and stress-reducing potential of *Withania somnifera*, validating its traditional use and encouraging further clinical integration.

3. RESULTS AND DISCUSSION:

Numerous preclinical and clinical studies have demonstrated the effectiveness of *Withania somnifera* in reducing stress and anxiety. The majority of human trials reported significant improvements in psychological well-being, reduced cortisol levels, and improved sleep quality without major adverse effects.

In a double-blind, placebo-controlled study by Chandrasekhar et al. (2012), 64 participants with chronic stress were administered 300 mg of high-concentration Ashwagandha extract twice daily for 60 days. The results showed a 44% reduction in perceived stress scale scores and a significant decrease in serum cortisol levels compared to the placebo group.

Auddy et al. (2008) demonstrated significant reductions in stress levels and improvement in overall well-being in individuals taking a standardized extract of Ashwagandha."

These findings align with other trials and systematic reviews affirming the herb's stress-relieving potential (Tandon & Yadav, 2020).

Another randomized controlled trial by Cooley et al. (2009) demonstrated that Ashwagandha, when combined with lifestyle counseling, significantly reduced anxiety scores measured by the Hamilton Anxiety Rating Scale (HAM-A). Participants reported improved mood, reduced fatigue, and enhanced quality of life.

Mechanistically, Ashwagandha works as an adaptogen by modulating the hypothalamic-pituitary-adrenal (HPA) axis and lowering cortisol secretion. It also exhibits GABA-mimetic activity, which may contribute to its calming effects on the central nervous system. Additionally, its antioxidant properties protect neurons from oxidative damage often associated with chronic stress.

Animal studies further support these findings. In rodent models, Ashwagandha extracts significantly reduced anxiety-like behavior in elevated plus maze and open field tests, comparable to standard anxiolytic drugs, but without sedative effects.

Collectively, these studies highlight Ashwagandha's efficacy as a safe, natural remedy for managing stress and anxiety. However, variations in dosage, extract type, and study design warrant further standardized, large-scale clinical trials for conclusive evidence.

Table 1: Summary of Key Clinical Trials on Ashwagandha in Stress and Anxiety Management

Study	Sample Size / Population	Dosage & Duration	Outcomes Measured	Key Findings
Chandrasekhar et al., 2012	64 adults with chronic stress	300 mg extract twice daily for 60 days	Perceived Stress Scale, serum cortisol	44% reduction in stress scores and significant cortisol reduction
Cooley et al., 2009	75 participants with anxiety symptoms	Ashwagandha + lifestyle intervention, 12 weeks	HAM-A (Hamilton Anxiety Rating Scale)	Significant reduction in anxiety symptoms compared to control
Lopresti et al., 2019	57 overweight aging males	240 mg/day, 8 weeks	Testosterone, cortisol, well-being	Improved vitality, reduced fatigue, slight cortisol reduction
Salve et al., 2019	60 stressed adults	125 mg and 300 mg twice daily, 8 weeks	PSS, cortisol, sleep quality	Dose-dependent stress and cortisol reduction; improved sleep
Pratte et al., 2014 (review)	Meta-analysis of human trials	Various	General stress/anxiety markers	Majority of trials report positive anxiolytic effects

4. CONCLUSION:

Withania somnifera (Ashwagandha) has emerged as a scientifically validated adaptogen with notable potential in the management of stress and anxiety. Its bioactive compounds, particularly withanolides, have been shown to modulate the hypothalamic-pituitary-adrenal (HPA) axis and enhance GABAergic activity, thereby promoting neuroendocrine stability and lowering cortisol levels (Singh et al., 2011; Chandrasekhar et al., 2012). Clinical studies consistently demonstrate significant improvements in stress biomarkers, anxiety scores, sleep quality, and overall psychological well-being, with a favorable safety profile (Cooley et al., 2009; Lopresti et al., 2019).

Given these findings, Ashwagandha shows strong promise as a complementary or alternative therapeutic option for managing stress and anxiety-related disorders. However, further standardized clinical trials with larger sample sizes, diverse populations, and long-term follow-up are necessary to confirm its efficacy and establish dosage guidelines for clinical use (Gupta et al., 2021). A comprehensive review concluded that Ashwagandha has a favorable safety profile with minimal side effects, especially when used in recommended therapeutic doses (Tandon & Yadav, 2020)."

REFERENCES

[1] Auddy, B., Hazra, J., Mitra, A., Abedon, B., & Ghosal, S. (2008). A standardized Withania somnifera extract significantly reduces stress-related parameters in chronically stressed humans: A double-blind, randomized, placebo-controlled study. Journal of the American Nutraceutical Association, 11(1), 50–56.

[2] Baldwin, D. S., Anderson, I. M., Nutt, D. J., Bandelow, B., Bond, A., Davidson, J. R., … & Wittchen, H. U. (2014). Evidence-based pharmacological treatment of anxiety disorders, post-traumatic stress disorder and obsessive-compulsive disorder: A revision of the 2005 guidelines from the British Association for Psychopharmacology. Journal of Psychopharmacology, 28(5), 403–439. https://doi.org/10.1177/0269881114525674

[3] Bhattacharya, S. K., Bhattacharya, A., Sairam, K., & Ghosal, S. (2000). Anxiolytic-antidepressant activity of Withania somnifera glycowithanolides: An experimental study. Phytomedicine, 7(6), 463–469. https://doi.org/10.1016/S0944-7113(00)80030-6

[4] Chandrasekhar, K., Kapoor, J., & Anishetty, S. (2012). A prospective, randomized double-blind, placebo-controlled study of safety and efficacy of a high-concentration full-spectrum extract of Ashwagandha root in reducing stress and anxiety in adults. Indian Journal of Psychological Medicine, 34(3), 255–262. https://doi.org/10.4103/0253-7176.106022

[5] Cooley, K., Szczurko, O., Perri, D., Mills, E. J., Bernhardt, B., & Seely, D. (2009). Naturopathic care for anxiety: A randomized controlled trial. PLoS ONE, 4(8), e6628. https://doi.org/10.1371/journal.pone.0006628

[6] Gupta, A., Kaur, G., & Bansal, P. (2021). Therapeutic potential of Withania somnifera: A mini-review. Journal of Ethnopharmacology, 275, 114098. https://doi.org/10.1016/j.jep.2021.114098

[7] Kuboyama, T., Tohda, C., & Komatsu, K. (2005). Neuritic regeneration and synaptic reconstruction induced by Withania somnifera in damaged neurons. NeuroReport, 16(6), 541–544. https://doi.org/10.1097/00001756-200504250-00005

[8] Lopresti, A. L., Smith, S. J., Malvi, H., & Kodgule, R. (2019). A randomized, double-blind, placebo-controlled, crossover study examining the hormonal and vitality effects of Ashwagandha (Withania somnifera) in aging, overweight males. American Journal of Men's Health, 13(1), 1–10. https://doi.org/10.1177/1557988319835985

[9] Panossian, A., & Wikman, G. (2008). Effects of adaptogens on the central nervous system and the molecular mechanisms associated with their stress-protective activity. Pharmaceuticals, 1(1), 85–102. https://doi.org/10.3390/ph1010085

[10] Singh, N., Bhalla, M., de Jager, P., & Gilca, M. (2011). An overview on Ashwagandha: A Rasayana (rejuvenator) of Ayurveda. African Journal of Traditional, Complementary and Alternative Medicines, 8(5 Suppl), 208–213. https://doi.org/10.4314/ajtcam.v8i5S.9

[11] Tandon, N., & Yadav, S. S. (2020). Safety and clinical effectiveness of Withania somnifera (L.) Dunal root in human ailments: A systematic review. Journal of Ethnopharmacology, 255, 112768. https://doi.org/10.1016/j.jep.2020.112768

[12] World Health Organization (WHO). (2021). Mental health and COVID-19: Early evidence of the pandemic's impact. Geneva: World Health Organization. https://www.who.int/publications/i/item/9789240024265

.